SPOTLIGHT: Novartis gets positive SPP100 Phase III results

Email LinkedIn
Tools

Novartis has received positive Phase III clinical results for SPP100, a once daily oral renin inhibitor for the treatment of hypertension. The company plans to submit SPP100 to the FDA in early 2006. Release

Filed Under